This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.


Are you an attendee? You will have received an email from noreply@spotme.com (check your junk) that provides you with access to the platform and the meeting.

Are you a presenter? You will have received a calendar invite and a direct Zoom link.


Need help quickly? Send an email to the GOC staff at enquiry@gyneoncology.ca or text 1-888-496-3662.


AGM highlights new advancements in research and practice in the field of gynecologic oncology. This engaging professional development event offers access to world-renowned speakers, plenary talks, abstract presentations, and so much more.

Upon completion of the conference, participants will be able to:

  1. Identify challenges related to indigenous health across Canada
  2. Discuss opportunities to support and improve gynecologic oncology care for indigenous communities.
  3. Review the exciting data related to secondary cytoreductive surgery in ovarian cancer and improve appropriate patient selection for this procedure.
  4. Describe the local and international surgical clinical trials landscape
  5. Assess recent Canadian research in gynecologic oncology.


This is a virtual meeting. Please note that all times in the agenda on this site are in PST.

Agenda

7

30AM

-

7

35AM

Welcome and Introduction

Tomer Feigenberg

7

35AM

-

8

35AM

Presidential Talk- The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health

Marcia Anderson

At the end of this session, participants will:
1. Understand the impact of racism on Indigenous health and health care.
2. Identify the human rights basis of Joyce's Principle.
3. Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.

8

40AM

-

9

05AM

Oral Abstract Presentations (3 min / 3 slides) and 2 min Q&A for each abstract presentation

Sarah MahCristina MitricElisabeth SpenardBrenna Swift

At the end of this session, participants should be able to evaluate the following studies: *Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift MD, MASc. *Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah MD MSc FRCSC. *Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah MD MSc FRCSC. *Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spenard MD, MSc. *Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.

9

05AM

-

9

50AM

First Break

Sponsor Symposium (15 min)

10

00AM

-

10

15AM

Video abstracts (3 minutes presentation and 2 minute Q&A)

Catriona BuickRevital Linder

At the end of this session, participants should be able to evaluate the following studies: * Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder MD. * Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick RN, PhD, CON(C).

10

15AM

-

10

45AM

Oral Abstract Presentations (7 min presentations and 3 min Q&A for each presentation)

Kristin BlackMaxime CôtéRachel Kim

At the end of this session, participants should be able to evaluate the following studies: * Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim MD, MHSc, FRCSC. * The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black MD FRCSC. * Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté MD.

10

45AM

-

11

45AM

12

00PM

-

1

15PM

Surgical Clinical Trials. Challenges and Opportunities

Andreas du BoisMarie PlanteMark Carey

This will be a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.

At the end of this session, participants will be able to: 1. Describe the framework leading to clinical trial approval in Canada. 2. Review recent successful Canadian initiated surgical clinical trials. 3. Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.

1

15PM

-

2

00PM

DeskTop Trials and Secondary Cytoreduction Debate

Andreas du BoisSusie Lau

The battle is on! Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau

At the end of this session, participants will be able to: 1. Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer. 2. Identify potential patients and indications for this procedure. 3. Discuss the clinical relevance and impact in the Canadian setting.

2

00PM

-

2

45PM

OvCAN Symposium

Barbara VanderhydenStephanie Lheureux, MD, PhDHelen MacKayAlicia Tone, PhD

At the end of this session, participants will be able to: 1. Summarize the vision/mission and goals of OvCan. 2. Review the trial that has applied a “one-two punch” by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease. 3. Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient’s journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.

2

45PM

-

2

55PM

2

55PM

-

3

00PM

Recordings

Presidential Talk

The Joyce Echaquan Inquiry: Learning and Unlearning in Indigenous Health by Dr. Marcia Anderson


At the end of this session, participants will:

  1. Understand the impact of racism on Indigenous health and health care.
  2. Identify the human rights basis of Joyce's Principle.
  3. Critically reflect on opportunities for action to improve health care quality for Indigenous Peoples.


Access the recording

Oral Abstract Presentations

3 min / 3 slides


At the end of this session, participants should be able to evaluate the following studies:

  • Oncologic and pregnancy outcomes after fertility sparing surgery for stage I, low grade endometrioid ovarian cancer - Brenna E. Swift, MD, MASc.
  • Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer centre: a quality improvement initiative - Sarah J. Mah, MD, MSc, FRCSC.
  • Quality of end-of-life care for women with gynecologic malignancies in Ontario, Canada: a 13-year population-based retrospective analysis - Sarah J. Mah, MD, MSc, FRCSC.
  • Apixaban for Postoperative Thromboprophylaxis as Standard of Care for Gynecologic Oncology Patients: A Real-World Data Study - Elisabeth Spénard MD, MSc.
  • Cost-analysis of an enhanced recovery program after minimally invasive gynecologic oncology surgery - Cristina Mitric MD.

Access the recording

Video Abstracts


At the end of this session, participants should be able to evaluate the following studies:

  • Laparoscopic repair of obturator nerve injury at the time of pelvic lymphadenectomy - Revital Linder, MD.
  • Predictors of Supportive Care in Young Women Diagnosed with a Gynecological Malignancy - Catriona J Buick, RN, PhD, CON(C).


Access the recording

Oral Abstract Presentations

7-min presentations and 3-min Q&A


At the end of this session, participants should be able to evaluate the following studies:

  • Are mismatch repair deficient endometrial cancer recurrences more salvageable than intact cohort? - Rachel Soyoun Kim, MD, MHSc, FRCSC.
  • The effect of transversus abdominis plane block on postoperative opioid use in gynecologic oncology patients undergoing laparotomy with Enhanced Recovery After Surgery (ERAS). - Kristin A Black, MD, FRCSC.
  • Are uterine manipulators harmful in minimally invasive surgery (MIS) for endometrial cancer? A retrospective cohort study. - Maxime Côté, MD.


Access the recording

Surgical Clinical Trials

Challenges and Opportunities


This is a panel of experts that will help you discover the world of surgical clinical trials from ideation to application. They will also cover constraints such as funding. The AGO perspective: Dr. Andreas Dubois. Surgical Trials in Cervix Cancer: The SHAPE of the future, Dr. Marie Plante. Surgical Gynecological Cancer Trials and the CCTG: Dr. Mark Carey.


At the end of this session, participants will be able to:

  1. Describe the framework leading to clinical trial approval in Canada.
  2. Review recent successful Canadian initiated surgical clinical trials.
  3. Discuss ways to engage more Canadian clinicians and centres in surgical clinical trials.

Access the recording

DeskTop Trials and Secondary Cytoreduction Debate


The battle is on!


Two debators will take a pro vs. con position on secondary cytoreductive surgery for recurrent ovarian cancer. Pros. Dr Andreas DuBois. vs. Cons. Dr Susie Lau.


At the end of this session, participants will be able to:

  1. Review available current literature related to secondary cytoreductive surgery in recurrent ovarian cancer.
  2. Identify potential patients and indications for this procedure.
  3. Discuss the clinical relevance and impact in the Canadian setting.

Access the recording

OvCAN Symposium

Dr. Barbara Vanderhyden, Dr. Stephanie Lheureux. Dr. Helen MacKay, Dr. Alicia Tone.


At the end of this session, participants will be able to:

  1. Summarize the vision/mission and goals of OvCan.
  2. Review the trial that has applied a "one-two punch" by combining the PARP inhibitor Veliparib with a second drug, Navitoclax. The two-pronged goal of this trial: to expand the benefits of this therapy to more women; and to prolong its effects in managing recurrences of the disease.
  3. Review the NEO Trial which aims to determine how early this new therapy can be introduced in an ovarian cancer patient's journey. The trial will compare the use of the PARP inhibitor Olaparib to standard chemotherapy applied immediately before and after surgery as a way to delay disease progression and reduce recurrences.


Access the recording

Abstract Book

Tickets

  • GOC Member Physicians

    C$225.-

    Member Price

    Buy Ticket
  • GOC Member Fellows

    C$110.-

    Member Price

    Buy Ticket
  • Other GOC Members

    C$110.-

    Member Price

    This ticket includes members in the following categories: emeritus, nurses, other healthcare professionals and resident associates

    Buy Ticket
  • Medical Student

    C$75.-

    Public Price

    Buy Ticket
  • Sponsor Representative

    Free

    Public Price

    This option is free for representatives up to the number of spots reserved for your organization as per your sponsorship level. If you are not on the final list submitted by your organization, you will be asked to attend as an "Other Non-Members." Connect with your organization's representative before registering.

    Reserve Ticket
  • Non-Member Physicians

    C$275.-

    Public Price

    Buy Ticket
  • Non-Member Fellows

    C$135.-

    Public Price

    Buy Ticket
  • Other Non-Members

    C$150.-

    Public Price

    Buy Ticket
  • Poster Presenter

    C$80.-

    Public Price

    This ticket is only open to those who have received a poster/video acceptance for their submitted abstract.

    Buy Ticket

Sponsors and Partners

Diamond

Bronze

Organizer

Gold